No patients have been given compassionate use or continuing to take the drug, as mentioned by Dr Stamler.
Dr Stamler also advised that most off these pts will unfortunately be too advanced to reassess in later time, so they would not qualify most likely, unless FDA approves off label administration with AA when it comes around.
So all future trials will be off new patients, although, also given latest detection findings, they could be significantly earlier as well.
Butall will be revealed VERY soon, as Dr Stamler advised he would like to have results out by their next meeting which is next weekend at the ANN meeting, so keep your eyes peeled Monday morning I recon.
ATH Price at posting:
0.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)